Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
Adams AM, Carpenter EL, Clifton GT, Vreeland TJ, Chick RC, O'Shea AE, McCarthy PM, Kemp Bohan PM, Hickerson AT, Valdera FA, Tiwari A, Hale DF, Hyngstrom JR, Berger AC, Jakub JW, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries MB, Peoples GE. Adams AM, et al. Among authors: vreeland tj. Cancer Immunol Immunother. 2023 Mar;72(3):697-705. doi: 10.1007/s00262-022-03272-8. Epub 2022 Sep 1. Cancer Immunol Immunother. 2023. PMID: 36045304 Free PMC article. Clinical Trial.
Operative standards for sentinel lymph node biopsy and axillary lymphadenectomy for breast cancer: review of the American College of Surgeons commission on cancer standards 5.3 and 5.4.
Zaveri S, Lillemoe HA, Teshome M, Reyna CR, Vreeland TJ, Francescatti AB, Zheng L, Hunt KK, Katz MHG, Kilgore LJ. Zaveri S, et al. Among authors: vreeland tj. Surgery. 2023 Sep;174(3):717-721. doi: 10.1016/j.surg.2023.04.007. Epub 2023 May 16. Surgery. 2023. PMID: 37202308 No abstract available.
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X, Wagner TE, Peoples GE. Greene JM, et al. Among authors: vreeland tj. Cancer Immunol Immunother. 2016 Apr;65(4):383-92. doi: 10.1007/s00262-016-1809-6. Epub 2016 Feb 19. Cancer Immunol Immunother. 2016. PMID: 26894495 Free PMC article. Clinical Trial.
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE. Jackson DO, et al. Among authors: vreeland tj. Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305. Oncotarget. 2017. PMID: 27852036 Free PMC article. Clinical Trial.
95 results